Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Basilea Pharmaceutica AG
  6. News
  7. Summary
    BSLN   CH0011432447

BASILEA PHARMACEUTICA AG

(BSLN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Basilea presents full safety and efficacy data set on derazantinib in patients with FGFR2 fusion-positive iCCA at ESMO congress

09/17/2021 | 01:15am EDT

(MORE TO FOLLOW) Dow Jones Newswires

September 17, 2021 01:15 ET (05:15 GMT)

All news about BASILEA PHARMACEUTICA AG
10/11BASILEA PHARMACEUTICA : Therapy Shows Synergistic Anti-Tumor Effects In Gastric Cancer Mod..
MT
10/11PRESS RELEASE : Basilea presents preclinical data -2-
DJ
10/11Basilea presents preclinical data on synergy between derazantinib and paclitaxel in gas..
DJ
10/11PRESS RELEASE : Basilea presents preclinical data on synergy between derazantinib and pacl..
DJ
10/11Basilea Pharmaceutica Ltd Presents Preclinical Data on Synergy Between Derazantinib and..
CI
09/30BASILEA PHARMACEUTICA : Asahi Kasei Seek Japanese Nod For Anti-Fungal Drug
MT
09/30Basilea's partner Asahi Kasei Pharma filed New Drug Application for the marketing autho..
DJ
09/30PRESS RELEASE : Basilea's partner Asahi Kasei Pharma filed New Drug Application for the ma..
DJ
09/30BASILEA PHARMACEUTICA : partner Asahi Kasei Pharma filed New Drug Application for the mark..
AQ
09/17BASILEA PHARMACEUTICA : Bile Duct Cancer Drug Shows Improved Efficacy In Updated Mid-Stage..
MT
More news
Analyst Recommendations on BASILEA PHARMACEUTICA AG
More recommendations
Financials
Sales 2021 138 M 149 M 149 M
Net income 2021 -22,2 M -24,1 M -24,1 M
Net cash 2021 0,85 M 0,93 M 0,93 M
P/E ratio 2021 -21,7x
Yield 2021 -
Capitalization 509 M 551 M 551 M
EV / Sales 2021 3,69x
EV / Sales 2022 3,02x
Nbr of Employees 160
Free-Float 88,5%
Chart BASILEA PHARMACEUTICA AG
Duration : Period :
Basilea Pharmaceutica AG Technical Analysis Chart | BSLN | CH0011432447 | MarketScreener
Technical analysis trends BASILEA PHARMACEUTICA AG
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Last Close Price 43,08 CHF
Average target price 87,60 CHF
Spread / Average Target 103%
EPS Revisions
Managers and Directors
David Veitch Chief Executive Officer
Adesh Kaul Chief Financial Officer
Domenico Scala Chairman
Laurenz Kellenberger Chief Scientific Officer
Marc Engelhardt Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
BASILEA PHARMACEUTICA AG-18.95%551
MODERNA, INC.210.34%130 866
LONZA GROUP AG26.90%58 060
IQVIA HOLDINGS INC.38.89%47 683
SEAGEN INC.-1.38%31 426
CELLTRION, INC.-38.72%25 414